Psychedelics like LSD and magic mushrooms could significantly enhance sexual well-being, offering promising alternatives to conventional treatments for sexual dysfunction, especially in those suffering from depression.
Researchers have discovered that ayahuasca, particularly due to its component harmine, acts as a powerful analgesic in mice without causing any detectable toxic effects.
Researchers debunked claims that THC-O-acetate produces psychedelic effects, finding instead that users primarily experienced moderate relaxation, euphoria, and pain relief without the profound cognitive or perceptual changes characteristic of classic psychedelics.
A global survey found that 70.9% of participants reported reducing or ceasing their use of non-psychedelic substances like alcohol and tobacco after using psychedelics, with psilocybin being the most influential.
Non-medical cannabis use is significantly associated with reduced odds of subjective cognitive decline (SCD) among U.S. adults aged 45 and older, according to new research.
Participants in an ayahuasca retreat reported a significant, sustained increase in aesthetic appreciation one week and one month post-consumption.
Researchers recently explored the potential of psilocybin, a compound from magic mushrooms, to combat diabetes. The findings suggest that psilocybin might protect pancreatic β-cells from damage.
LSD increases neural complexity and reduces certain brain wave frequencies, which correlates with feelings of elation, according to new research.
A pivotal study explored how patient expectations affect psilocybin therapy outcomes, discovering no significant impact. Interestingly, suggestible individuals showed enhanced benefits, suggesting a unique interplay between mindset and psychedelic therapy effectiveness.
A new study provides evidence that mushroom extract containing psilocybin may offer superior therapeutic effects for psychiatric disorders compared to synthetic psilocybin, suggesting an "entourage effect" of additional compounds enhancing treatment outcomes.
Psilocybin therapy alters brain activity in patients with alcohol use disorder, according to new research, increasing activity in areas associated with emotional regulation and reducing activity in regions linked to craving.
A groundbreaking study sheds light on psilocybin therapy's success in treating depression, highlighting the crucial roles of mystical experiences and ego dissolution, enhanced by music, in surpassing traditional treatments. The findings were published in the International Journal of Mental Health...
A JAMA Psychiatry study explores the link between psychedelic use in adolescents and mental health, finding an association with fewer psychotic symptoms and a correlation with increased manic symptoms in those with genetic risks for schizophrenia or bipolar disorder.
A study found ketamine's rapid antidepressant effects in rats hinge on activating the brain's opioid system, particularly β-endorphin in the prefrontal cortex. Blocking this pathway negates ketamine's benefits, unveiling potential targets for new depression treatments.
A twin study found cannabis use has limited direct impact on psychological outcomes, attributing most associations to genetics and environment. However, modest effects on cannabis disorder and illicit drug use were noted, challenging simplistic narratives about cannabis's negative effects.